Erick Campbell
Overview
Explore the profile of Erick Campbell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, et al.
Clin Cancer Res
. 2024 Apr;
30(14):2986-2995.
PMID: 38687597
Purpose: We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications. Experimental Design: Gynecologic cancers with available somatic molecular...
2.
Nelson B, Roszik J, Ahmed J, Barretto C, Nardo M, Campbell E, et al.
Mol Cancer
. 2024 Mar;
23(1):64.
PMID: 38532456
Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged...
3.
Pilie P, Giuliani V, Wang W, McGrail D, Bristow C, Ngoi N, et al.
Clin Cancer Res
. 2024 Feb;
30(10):2121-2139.
PMID: 38416404
Purpose: Mutations in the ATM gene are common in multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement of ATM loss of function (LOF)...
4.
Barber F, Campbell E, Yamamura Y, Patterson C, Hartnett A, Kinahan H, et al.
J Adv Pract Oncol
. 2022 Oct;
13(7):664-672.
PMID: 36199491
Background: Advanced practice providers (APPs) play important roles in enrolling, educating, and caring for patients in clinical trials. However, much remains unknown about the role of APPs in managing adverse...
5.
Nelson B, Ejezie C, Stephen B, Nardo M, Campbell E, Gong J, et al.
J Hematol
. 2022 Jul;
11(3):113-120.
PMID: 35837373
Immune checkpoint inhibitor anemias (ICI-A) are a rare entity which can be potentially life-threatening without prompt identification. The goal of the study is to characterize the presentation, evaluation, and outcomes...
6.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul S, et al.
Sci Rep
. 2022 May;
12(1):8701.
PMID: 35610322
Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of...
7.
Alhalabi O, Hahn A, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, et al.
Clin Genitourin Cancer
. 2021 Aug;
20(1):e16-e24.
PMID: 34362693
Introduction: Enrolling patients with metastatic urothelial carcinoma (mUC) in phase I trials provides an opportunity to identify biological drug activity. Developing prognostic scores may aid in patient selection for phase...
8.
Alhalabi O, Hahn A, Msaouel P, Andreev-Drakhlin A, Meric-Bernstam F, Naing A, et al.
Mol Cancer Res
. 2020 Dec;
19(3):395-402.
PMID: 33323389
Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC)...
9.
Hahn A, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, et al.
ESMO Open
. 2020 Nov;
5(6):e001073.
PMID: 33229506
Background: For patients with metastatic renal cell carcinoma (mRCC) who progress on standard-of-care therapies, there is an unmet need for novel treatments. Phase I clinical trials are designed to test...